146 related articles for article (PubMed ID: 2966782)
1. Preparation and biodistribution of [125I]IBZM: a potential CNS D-2 dopamine receptor imaging agent.
Kung HF; Guo YZ; Billings J; Xu X; Mach RH; Blau M; Ackerhalt RE
Int J Rad Appl Instrum B; 1988; 15(2):195-201. PubMed ID: 2966782
[TBL] [Abstract][Full Text] [Related]
2. Preparation and biodistribution of [125I]IBZP: a potential CNS D-1 dopamine receptor imaging agent.
Kung HF; Billings JJ; Guo YZ; Blau M; Ackerhalt R
Int J Rad Appl Instrum B; 1988; 15(2):187-93. PubMed ID: 2966781
[TBL] [Abstract][Full Text] [Related]
3. [In vivo characteristics of IBZM in rat brains: an agent for quantitative SPECT imaging of dopamine D2 receptors. Preparation of 125I-IBZM and its biodistribution and kinetic properties].
Matsumura K; Toyama H; Nakashima H; Ichise M; Kurami M; Nakagawa T; Maeda H; Takeuchi A; Koga S
Kaku Igaku; 1994 May; 31(5):513-9. PubMed ID: 8028224
[TBL] [Abstract][Full Text] [Related]
4. Comparison of in vivo D-2 dopamine receptor binding of IBZM and NMSP in rat brain.
Kung HF; Billings JJ; Guo YZ; Mach RH
Int J Rad Appl Instrum B; 1988; 15(2):203-8. PubMed ID: 2966783
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent.
Kung HF; Pan S; Kung MP; Billings J; Kasliwal R; Reilley J; Alavi A
J Nucl Med; 1989 Jan; 30(1):88-92. PubMed ID: 2783457
[TBL] [Abstract][Full Text] [Related]
6. In vitro binding properties and autoradiographic imaging of 3-iodobenzamide ([125I]-IBZM): a potential imaging ligand for D-2 dopamine receptors in SPECT.
Brücke T; Tsai YF; McLellan C; Singhanyom W; Kung HF; Cohen RM; Chiueh CC
Life Sci; 1988; 42(21):2097-104. PubMed ID: 3260318
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, in vitro binding profile and biodistribution of a 125I-labeled N-benzyl pyrrolidinyl benzamide derivative: a potential radioligand for mapping dopamine D2 receptors.
Saji H; Tanahashi K; Kinoshita T; Iida Y; Magata Y; Yokoyama A
Nucl Med Biol; 1996 Feb; 23(2):121-7. PubMed ID: 8868283
[TBL] [Abstract][Full Text] [Related]
8. Comparison of in vivo dopamine D2 receptor binding of [(123)I]AIBZM and [(123)I]IBZM in rat brain.
Li H; Gildehaus FJ; Dresel S; Patt JT; Shen M; Zhu T; Liu B; Tang Z; Tatsch K; Hahn K
Nucl Med Biol; 2001 May; 28(4):383-9. PubMed ID: 11395310
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain.
Verhoeff NP; Bobeldijk M; Feenstra MG; Boer GJ; Maas MA; Erdtsieck-Ernste E; de Bruin K; van Royen EA
Int J Rad Appl Instrum B; 1991; 18(8):837-46. PubMed ID: 1839302
[TBL] [Abstract][Full Text] [Related]
10. Dopamine D-2 receptor imaging radiopharmaceuticals: synthesis, radiolabeling, and in vitro binding of (R)-(+)- and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N- [(1-ethyl-2-pyrrolidinyl)methyl]benzamide.
Kung HF; Kasliwal R; Pan SG; Kung MP; Mach RH; Guo YZ
J Med Chem; 1988 May; 31(5):1039-43. PubMed ID: 2966245
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents.
Murphy RA; Kung HF; Kung MP; Billings J
J Med Chem; 1990 Jan; 33(1):171-8. PubMed ID: 2136916
[TBL] [Abstract][Full Text] [Related]
12. The characterization of IBF as a new selective dopamine D-2 receptor imaging agent.
Kung MP; Kung HF; Billings J; Yang Y; Murphy RA; Alavi A
J Nucl Med; 1990 May; 31(5):648-54. PubMed ID: 2140409
[TBL] [Abstract][Full Text] [Related]
13. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans.
Kung HF; Alavi A; Chang W; Kung MP; Keyes JW; Velchik MG; Billings J; Pan S; Noto R; Rausch
J Nucl Med; 1990 May; 31(5):573-9. PubMed ID: 2140408
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK
Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317
[TBL] [Abstract][Full Text] [Related]
15. [A fundamental study on accumulation of [125I]IBZM in the rat striatum and on effect of non-labeled ligand].
Ishikawa N; Nakamura T; Motoji N; Satou M; Takeda T; Wu J; Shigematsu A
Kaku Igaku; 1995 Jan; 32(1):81-6. PubMed ID: 7897871
[TBL] [Abstract][Full Text] [Related]
16. The toxicity and mutagenicity of S-3-iodo-N-(1-ethyl-2-pyrrolidinyl)methyl-2-hydroxy-6-methoxybenzamide (IBZM), a new CNS D-2 dopamine receptor imaging agent.
Kostyniak PJ; Brenner JS; Maccubbin AE; Nakeeb S; Kasliwal R; Kung HF
Drug Chem Toxicol; 1988; 11(4):433-42. PubMed ID: 2977324
[TBL] [Abstract][Full Text] [Related]
17. Comparison of intravenous and intraperitoneal [123I]IBZM injection for dopamine D2 receptor imaging in mice.
Meyer PT; Salber D; Schiefer J; Cremer M; Schaefer WM; Kosinski CM; Langen KJ
Nucl Med Biol; 2008 Jul; 35(5):543-8. PubMed ID: 18589298
[TBL] [Abstract][Full Text] [Related]
18. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM
J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
[TBL] [Abstract][Full Text] [Related]
19. Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).
Staedt J; Stoppe G; Kögler A; Riemann H; Hajak G; Munz DL; Emrich D; Rüther E
J Neural Transm Gen Sect; 1995; 99(1-3):187-93. PubMed ID: 8579804
[TBL] [Abstract][Full Text] [Related]
20. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.
Leslie WD; Abrams DN; Greenberg CR; Hobson D
J Nucl Med; 1996 Oct; 37(10):1589-91. PubMed ID: 8862288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
